The effect of induction ALG (MALG) on the outcome of steroid-resistant rejection treated with OKT3 in renal transplant patients.
Chiu
A
A
Department of Medicine, University of British Columbia, Vancouver.
Landsberg
D
D
Cameron
E C
EC
Manson
A D
AD
Shackleton
C
C
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D003141:Communicable Diseases / Q000150:complications; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000276:immunology / Q000379:methods*; D016853:Muromonab-CD3; D016019:Survival Analysis; D013997:Time Factors
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3